Fennec Pharmaceuticals Grants Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy FENC?
Source: Newsfilter
- Stock Option Grant: On March 31, 2026, Fennec Pharmaceuticals granted a total of 377,500 incentive stock options to 24 new non-executive employees, with an exercise price of $5.77 per share, aimed at attracting talent and enhancing team stability.
- Inducement Plan Context: The stock options were granted under Nasdaq Listing Rule 5635(c)(4), specifically designed for individuals who were not previously employed by the company, reflecting the company's commitment to new hires and future growth.
- Option Structure: One-third of each option vests on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the next 24 months, ensuring employee retention and loyalty through continued employment.
- Market Outlook: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, and the exclusive licensing agreement with Norgine is expected to further expand market reach and enhance the company's competitive position in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FENC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FENC
Wall Street analysts forecast FENC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.790
Low
13.00
Averages
14.67
High
18.00
Current: 6.790
Low
13.00
Averages
14.67
High
18.00
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
University of Arizona Initiates Study on PEDMARK® for Cancer Patients
- Study Initiation: The University of Arizona Cancer Center has launched a study to evaluate the use of PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin, marking an expansion of real-world validation for PEDMARK® across new tumor types.
- Clinical Utility Assessment: Tampa General Hospital Cancer Institute has also initiated a study to assess the clinical utility of PEDMARK® in reducing the risk of ototoxicity in AYA and adult cancer patients undergoing cisplatin treatment, indicating a potential positive impact on patient quality of life.
- Concurrent Research Efforts: Fennec Pharmaceuticals recently announced that, in addition to the University of Arizona study, two other independent institution-led studies are underway, further supporting the application of PEDMARK® in various tumor types and patient populations.
- Strategic Implications: Fennec's Chief Medical Officer emphasized that supporting independent research helps build real-world evidence, facilitating broader clinical adoption of PEDMARK®, which suggests potential label expansion and increased market acceptance in the future.
See More
Fennec Pharmaceuticals Reveals Investigator-Led Research to be Conducted by the University of Arizona Cancer Center
- Study Announcement: A sponsored study will be conducted by the University of Arizona Cancer Center.
- Focus of Research: The study aims to investigate specific aspects related to pharmaceuticals and cancer treatment.
See More
Fennec Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On March 31, 2026, Fennec Pharmaceuticals granted a total of 377,500 incentive stock options to 24 new non-executive employees, with an exercise price of $5.77 per share, aimed at attracting talent and enhancing team stability.
- Inducement Plan Context: The stock options were granted under Nasdaq Listing Rule 5635(c)(4), specifically designed for individuals who were not previously employed by the company, reflecting the company's commitment to new hires and future growth.
- Option Structure: One-third of each option vests on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the next 24 months, ensuring employee retention and loyalty through continued employment.
- Market Outlook: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, and the exclusive licensing agreement with Norgine is expected to further expand market reach and enhance the company's competitive position in the pharmaceutical industry.
See More
Fennec Pharmaceuticals Q4 2025 Earnings Report
- Disappointing Earnings: Fennec Pharmaceuticals reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.21, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Despite a 73.8% year-over-year revenue increase to $13.78 million, the figure fell short of expectations by $0.95 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Strong Cash Position: As of December 31, 2025, the company had $36.8 million in cash and cash equivalents, representing a $10.2 million increase from the previous year, demonstrating effective cash management that supports future operations and R&D.
- No Debt Burden: Fennec Pharmaceuticals reported zero outstanding debt as of December 31, 2025, providing financial flexibility that may help mitigate risks in future investments and expansions.
See More
FENNEC PHARMACEUTICALS INC Reports Q4 2025 Net Product Sales of $13.8 Million
- Sales Performance: The pharmaceutical company reported net product sales of $13.8 million for the fourth quarter of 2025.
- Financial Outlook: The sales figures indicate a positive trend in the company's financial performance within the pharmaceutical sector.
See More
Fennec Pharmaceuticals Announces Financial Results for Q4 and Full Year 2025 Along with Business Update
Financial Results: The report covers the financial results for the fourth quarter and the full year of 2025 for a pharmaceutical company.
Business Update: It provides a business update, likely detailing performance metrics, strategic initiatives, and future outlook.
See More
University of Arizona Initiates Study on PEDMARK® for Cancer Patients
- Study Initiation: The University of Arizona Cancer Center has launched a study to evaluate the use of PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin, marking an expansion of real-world validation for PEDMARK® across new tumor types.
- Clinical Utility Assessment: Tampa General Hospital Cancer Institute has also initiated a study to assess the clinical utility of PEDMARK® in reducing the risk of ototoxicity in AYA and adult cancer patients undergoing cisplatin treatment, indicating a potential positive impact on patient quality of life.
- Concurrent Research Efforts: Fennec Pharmaceuticals recently announced that, in addition to the University of Arizona study, two other independent institution-led studies are underway, further supporting the application of PEDMARK® in various tumor types and patient populations.
- Strategic Implications: Fennec's Chief Medical Officer emphasized that supporting independent research helps build real-world evidence, facilitating broader clinical adoption of PEDMARK®, which suggests potential label expansion and increased market acceptance in the future.
See More
Fennec Pharmaceuticals Reveals Investigator-Led Research to be Conducted by the University of Arizona Cancer Center
- Study Announcement: A sponsored study will be conducted by the University of Arizona Cancer Center.
- Focus of Research: The study aims to investigate specific aspects related to pharmaceuticals and cancer treatment.
See More
Fennec Pharmaceuticals Grants Stock Options to New Employees
- Stock Option Grant: On March 31, 2026, Fennec Pharmaceuticals granted a total of 377,500 incentive stock options to 24 new non-executive employees, with an exercise price of $5.77 per share, aimed at attracting talent and enhancing team stability.
- Inducement Plan Context: The stock options were granted under Nasdaq Listing Rule 5635(c)(4), specifically designed for individuals who were not previously employed by the company, reflecting the company's commitment to new hires and future growth.
- Option Structure: One-third of each option vests on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the next 24 months, ensuring employee retention and loyalty through continued employment.
- Market Outlook: Fennec focuses on the commercialization of PEDMARK® to reduce the risk of ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, and the exclusive licensing agreement with Norgine is expected to further expand market reach and enhance the company's competitive position in the pharmaceutical industry.
See More
Fennec Pharmaceuticals Q4 2025 Earnings Report
- Disappointing Earnings: Fennec Pharmaceuticals reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.21, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Despite a 73.8% year-over-year revenue increase to $13.78 million, the figure fell short of expectations by $0.95 million, reflecting intensified market competition and potential shortcomings in sales strategies.
- Strong Cash Position: As of December 31, 2025, the company had $36.8 million in cash and cash equivalents, representing a $10.2 million increase from the previous year, demonstrating effective cash management that supports future operations and R&D.
- No Debt Burden: Fennec Pharmaceuticals reported zero outstanding debt as of December 31, 2025, providing financial flexibility that may help mitigate risks in future investments and expansions.
See More
FENNEC PHARMACEUTICALS INC Reports Q4 2025 Net Product Sales of $13.8 Million
- Sales Performance: The pharmaceutical company reported net product sales of $13.8 million for the fourth quarter of 2025.
- Financial Outlook: The sales figures indicate a positive trend in the company's financial performance within the pharmaceutical sector.
See More
Fennec Pharmaceuticals Announces Financial Results for Q4 and Full Year 2025 Along with Business Update
Financial Results: The report covers the financial results for the fourth quarter and the full year of 2025 for a pharmaceutical company.
Business Update: It provides a business update, likely detailing performance metrics, strategic initiatives, and future outlook.
See More
